Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ECLIPSE: J&J's Tremfya Beats Novartis' Cosentyx For Long-Term Psoriasis Clearance

Executive Summary

Novartis stresses long-term safety database for Cosentyx – with five years' worth of data in three indications – psoriasis, psoriatic arthritis and ankylosing spondylitis.

Advertisement

Related Content

Carry On Cosentyx As Novartis Lines Up More Blockbusters
Q4 Earnings Preview: Pfizer, Amgen, Allergan, Biogen And Novartis
Eight Things To Know From Novartis' Third Quarter Call
J&J Pharma Growth Led By Oncology; Firm Tries To Assuage Zytiga Concerns
J&J Growth Plans Heavy On Line Extensions, Sticking With Immunology And Oncology
Novartis Allays Concerns Over Cosentyx Sales Miss
J&J's First-In-Class Tremfya Poised To Join A Crowded Psoriasis Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124338

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel